GlobeNewswire by notified

Ambiq Apollo510 Delivers 30x Power Efficiency Improvement to Unleash Endpoint AI

Share

The next-generation Apollo pairs vector acceleration with unmatched power efficiency to enable most AI inferencing on-device without a dedicated NPU

Feature Highlights

  • Apollo510, based on Arm Cortex-M55, delivers 30x better power efficiency and 10x faster performance compared to previous generations
  • The ability to do AI/ML workloads concurrent with complex graphics, telco-quality voice applications, and always-on voice/sensor processing
  • 4 MB on-chip NVM, 3.75 MB on-chip SRAM, and high bandwidth interfaces to off-chip memories
  • 2.5D GPU with vector graphics acceleration for vibrant, crystal-clear, and smooth graphics, a 3.5x overall performance enhancement over the Apollo4 Plus family
  • Support for Memory in Pixel (MiP) displays, typically found in the lowest-power products
  • Robust security on Ambiq's secureSPOT® platform with Arm TrustZone technology

AUSTIN, Texas, March 26, 2024 (GLOBE NEWSWIRE) -- Ambiq, a technology leader in exceptionally energy-efficient semiconductors for IoT devices, is introducing the new Apollo510, the first member of the Apollo5 SoC family, which is uniquely positioned to kickstart the age of truly ubiquitous, practical, and meaningful AI.

The Apollo510 MCU is a complete overhaul of hardware and software that fully leverages the Arm® Cortex®-M55 CPU with Arm Helium™ to reach processing speeds up to 250MHz. The Apollo510 achieves up to 10x better latency while reducing energy consumption by around 2x, compared to Ambiq's previous power efficiency leader, the Apollo4. This desirable combination of performance and efficiency allows our customers to deploy sophisticated speech, vision, health, and industrial AI models on battery-powered devices everywhere, making it the most efficient semiconductor on the market to operate with the Arm Cortex-M55.

"We at Ambiq have pushed our proprietary SPOT platform to optimize power consumption in support of our customers, who are aggressively increasing the intelligence and sophistication of their battery-powered devices year after year," said Scott Hanson, Ambiq's CTO and Founder. The new Apollo510 MCU is simultaneously the most energy-efficient and highest-performance product we've ever created."

"As applications across health, industrial, and smart home continue to advance, the need for secure edge AI is crucial for next generation devices," said Paul Williamson, SVP and GM, IoT Line of Business at Arm. "Ambiq's new family of SoCs, built on Arm, will deliver significant performance gains for on-device AI, helping developers and device manufacturers deliver the capabilities required for the AI era."

With more than 30x energy improvement, the Apollo510 is capable of running a vast majority of today's endpoint AI calculations, including low-power sensor monitoring, always-on voice commands, telco-quality audio enhancement, and more. Manufacturers of IoT devices that perform AI/ML inferencing, such as next-gen wearables, digital health devices, AR/VR glasses, factory automation, and remote monitoring devices, can greatly expand their power budget while adding more capabilities to their devices through the Apollo510's SPOT-optimized design.

Apollo510 contains everything needed for driving intelligent systems: ultra-efficient compute, expansive on-chip memories, high-bandwidth interfaces to off-chip memories, and security. Arm Helium technology on Apollo510 supports up to 8 MACs per cycle as well as half, full, and double precision floating point operations, making it ideal for AI calculations in addition to general signal processing operations. Apollo510 also improves its memory capacity over the previous generation with 4 MB of on-chip NVM and 3.75 MB of on-chip SRAM and TCM, so developers have smooth development and more application flexibility. For extra-large neural network models or graphics assets, Apollo510 has a host of high bandwidth off-chip interfaces, individually capable of peak throughputs up to 500MB/s and sustained throughput over 300MB/s.

Building upon Ambiq's secureSPOT platform, Apollo510 integrates Arm TrustZone technology with a physical unclonable function (PUF), tamper-resistant OTP, and secure peripherals. These enhancements help designers establish a trusted execution environment (TEE) to develop secure, robust applications and scale their products faster.

IoT endpoint device manufacturers can expect unrivaled power efficiency to develop more capable devices that process AI/ML functions better than before. Targeted applications and industries include wearables, digital health, agriculture, smart homes and buildings, predictive maintenance, factory automation, and more.

The Apollo510 MCU is currently sampling with customers, with general availability in Q4 this year. It has been nominated by the 2024 embedded world community under the Hardware category for the embedded awards.

Meet us at the Embedded World Exhibition and Conference on April 9- 11, 2024, for a live product demonstration.

About Ambiq
Ambiq's mission is to develop the lowest-power semiconductor solutions to enable intelligent devices everywhere and drive a more energy-efficient, sustainable, and data-driven world. Ambiq has helped leading manufacturers worldwide develop products that last weeks on a single charge (rather than days) while delivering a maximum feature set in compact industrial designs. Ambiq's goal is to take Artificial Intelligence (AI) where it has never gone before in mobile and portable devices, using Ambiq's advanced ultra-low power system on chip (SoC) solutions. Ambiq has shipped more than 230 million units. For more information, visit www.ambiq.com.

Contact
Charlene Wan 
VP of Branding, Marketing, and Investor Relations 
cwan@ambiq.com
+1.512.879.2850 

Photos accompanying this announcement are available at: 

https://www.globenewswire.com/NewsRoom/AttachmentNg/d64aa7b3-31bb-457a-8a24-8fed2fbbea57

https://www.globenewswire.com/NewsRoom/AttachmentNg/998624f8-ab5f-46a8-89df-53e125d82767

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors23.4.2024 19:42:34 CEST | Press release

Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patients Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a rare cancer that is often unresectable and commonly diagnosed in the late stages of disease Novartis, a leader in radioligand therapy (RLT), is investigating a portfolio of RLTs to treat a broad range of cancers, including GEP-NETs, lung, prostate, breast, colon, brain and pancreatic cancers Basel, April 23, 2024 – Novartis today announced that the U.S. Food and Drug Administration (FDA) approved Lutathera® (USAN: lutetium Lu 177 dotatate / INN: lutetium (177Lu) oxodotreotide) for the treatment of pediatric patients 12 years and older with somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut NETs. This approval makes Lutathera the first therapy specifically reviewed and appro

Grant of warrants23.4.2024 19:20:21 CEST | Press release

23 April 2024 Announcement no. 9 Grant of Warrants COPENHAGEN, DENMARK and BOSTON, MA, USA, April 23, 2024 (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) has resolved, in accordance with the annual general meeting’s resolution on April 27, 2023, to issue a total of 4,000,000 warrants to members of the Executive Management. Each warrant grants the holder the right to subscribe for one share in BioPorto. The exercise price is DKK 1.23 per share, corresponding to the closing price today on Nasdaq Copenhagen. The warrants are issued in accordance with section 18 a of the Articles of Association. Half of the warrants vest over a 2-year period, and the remaining half upon completion of a qualified capital raise in the Company with terms of qualification (including timing and amount of proceeds) to be defined by the Board of Directors. The warrants are otherwise subject to the Company’s incentive warrant program as included in Appendix 1 o

TrueCommerce leverer globale e-fakturerings- og CTC-løsninger til virksomheder, der har udfordringer med overholdelse23.4.2024 19:10:28 CEST | pressemeddelelse

Virksomheden er ene om at tilbyde en global løsning, der omfatter e-fakturering, CTC-løsninger og et omfattende EDI-netværk, alt sammen problemfritintegreret med B2B e-handels- og ERP-systemer KØBENHAVN, Danmark, April 23, 2024 (GLOBE NEWSWIRE) -- TrueCommerce, en global leverandør af forsyningskæde- og handelspartnerforbindelser, integration og løsninger via flere kanaler, har i dag givet meddelelse om sin globale løsning til e-fakturering og Continuous Transaction Controls (CTC), der gør det muligt for organisationer at holde trit med de konstant skiftende juridiske krav overalt i verden og understøtter elektronisk fakturering, som opfylder de gældende krav. TrueCommerce er en global markedsaktør, der understøtter både e-fakturering og CTC og giver adgang til et omfattende globalt EDI-netværk samt B2B e-handel og ERP-integration. På grund af kompleksiteten i at navigere i et landskab af stadigt skiftende landespecifikke e-faktureringskrav og deadlines, står virksomheder over for en s

Festi hf.: Financial results for Q1 202423.4.2024 19:02:17 CEST | Press release

Key findings Sale of goods amounted to ISK 32,223 million, compared to ISK 29,484 million in the previous year, an increase of 9.3% between years.Gross profit from sales of goods and services amounted to ISK 7,033 million, an increase of 806 million or 12.9% between years.Profit Margins from sales of goods and services were 21.8% and increases by 0.7 p.p. from Q1 2023 but decreases by 1.2 p.p. from Q4 2023.Salaries and other personnel expenses increase by 7.5% and full-time equivalents by 2.5%.EBITDA amounted to ISK 1,898 million compared to ISK 1,401 million in Q1 2023, increase of 35.5% between years. Profit for the quarter amounted to ISK 202 million, or 2.9% of margin, a turnaround of ISK 293 million YoY.Net cash from operating activities was ISK 538 million or 7.6% of margin, compared to ISK 1,238 million last year.Equity at the end of Q1 2024 amounted to ISK 35,140 million with an equity ratio of 36.0%. EBITDA forecast for the year 2024 is raised by ISK 300 million and is now ISK

ASM reports first quarter 202423.4.2024 18:00:00 CEST | Press release

Almere, The Netherlands April 23, 2024, 6 p.m. CET Solid start of the year, Q1 orders supported by GAA and HBM ASM International N.V. (Euronext Amsterdam: ASM) today reports its Q1 2024 results (unaudited). Financial highlights € millionQ1 2023Q4 2023Q1 2024 New orders 647.4 677.5 697.9 yoy change % at constant currencies (6%) (14%) 10% Revenue 710.0 632.9 639.0 yoy change % at constant currencies 40% (7%) (8%) Gross profit margin % 49.4 % 47.2 % 52.9 % Adjusted gross profit margin 1 51.1 % 47.9 % 52.9 % Operating result 204.2 131.5 187.1 Operating result margin % 28.8 % 20.8 % 29.3 % Adjusted operating result 1 221.2 141.0 191.8 Adjusted operating result margin 1 31.2 % 22.3 % 30.0 % Net earnings 380.4 90.9 173.1 Adjusted net earnings 1 183.0 100.3 178.9 1 Adjusted figures are non-IFRS performance measures (previously referred to as "normalized"). Refer to Annex 3 for a reconciliation of non-IFRS performance measures. New orders of €698 million in Q1 2024 increased by 10% at constant

HiddenA line styled icon from Orion Icon Library.Eye